SARS-CoV-2-IN-109

Description

SARS-CoV-2-IN-109 compound 50 is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain RBD and the human receptor angiotensin-converting enzyme 2 ACE2 EC50=26.5 ?M , blocking the entry of SARS-CoV-2 into VeroE6 cells EC50=17.0 ?M . The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 ?M.